LONDON (BUSINESS WIRE) JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited (“Zura”), a clinical-stage biotechnology company.At the extraordinary general mee.
JATT Acquisition Corp (NYSE: JATT, JATT.WS and JATT.U) (the "Company"), a publicly-traded special purpose acquisition company, today announced that it will voluntarily transfer the listing of its Class
Record date of Feb 26th 2023 established as well as; Extraordinary general meeting of shareholders to approve the Business Combination set for March 16th 2023 JATT Acquisition Corp (NYSE:
Company advancing ZB-168, an anti-IL7R monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values the combined companies at a pro forma
JATT Acquisition Corp Prices $120 Million Initial Public Offering apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.